Short answer · Medically reviewed summary · Last updated: 2026-04-06
Currently, there is no medical cure for Sjogren, a systemic autoimmune condition where the immune system attacks moisture-producing glands and potentially other organ systems. Focusing on Management and Remission While we cannot yet permanently reverse the underlying autoimmune process of Sjogren, modern medicine has made significant strides in symptom management and disease modification. Current treatments, including hydroxychloroquine, immunosuppressants, and biologics, aim to reduce systemic inflammation, protect organ function, and improve quality of life.
1 people with Sjogren have shared their first-person experience on this question at DiseaseMaps.
Currently, there is no medical cure for Sjogren, a systemic autoimmune condition where the immune system attacks moisture-producing glands and potentially other organ systems.
While we cannot yet permanently reverse the underlying autoimmune process of Sjogren, modern medicine has made significant strides in symptom management and disease modification. Current treatments, including hydroxychloroquine, immunosuppressants, and biologics, aim to reduce systemic inflammation, protect organ function, and improve quality of life. For many patients, the goal is achieving clinical remission or low disease activity, which can prevent the long-term complications like nerve damage or vasculitis associated with the disease.
The research landscape for Sjogren is more active than ever before. Scientists are moving beyond broad immunosuppression toward precision medicine, which seeks to target the specific molecular pathways driving an individual’s disease. Investigational therapies currently in clinical trials are exploring B-cell depletion, the inhibition of specific cytokines (such as BAFF or IL-17), and the use of Janus kinase (JAK) inhibitors to modulate the immune response more selectively.
While gene therapy for Sjogren remains in the early, experimental stages, researchers are utilizing advanced genomic sequencing to better understand the genetic predisposition to this condition. Patients interested in contributing to scientific breakthroughs should explore opportunities at ClinicalTrials.gov to see if they meet the criteria for ongoing Phase II or III trials. Given the complexity of the disease, experts anticipate that the next decade will likely yield more targeted "disease-modifying" therapies rather than a single "cure." To stay informed, I recommend following updates from the Sjögren’s Foundation and the NIH’s Genetic and Rare Diseases Information Center (GARD).
Medical Disclaimer: This information is for educational purposes only and does not constitute medical advice. Please consult with your rheumatologist or a specialist at a dedicated center for autoimmune diseases before making any changes to your treatment plan.